Editas Medicine, Inc. Stock Compensation Disclosure
| Year Ended December 31, | |||||||||||
| 2024 | 2023 | ||||||||||
| Research and development | $ | 8,642 | $ | 9,842 | |||||||
| General and administrative | 12,775 | 9,956 | |||||||||
| Total stock-based compensation expense | $ | 21,417 | $ | 19,798 | |||||||
| Shares | Weighted Average Grant Date Fair Value Per Share | ||||||||||
| Unvested restricted stock and restricted stock unit awards as of December 31, 2023 | 2,107,147 | $ | 11.96 | ||||||||
| Issued | 1,504,321 | $ | 9.17 | ||||||||
| Vested | (730,157) | $ | 12.58 | ||||||||
| Forfeited | (554,788) | $ | 12.71 | ||||||||
| Unvested restricted stock and restricted stock unit awards as of December 31, 2024 | 2,326,523 | $ | 9.78 | ||||||||
| Shares | Weighted Average Exercise Price | Remaining Contractual Life (years) | Aggregate Intrinsic Value (in thousands) | ||||||||||||||||||||
| Outstanding at December 31, 2023 | 6,149,645 | $ | 16.47 | 6.98 | $ | 3,195 | |||||||||||||||||
| Granted | 2,966,836 | $ | 8.07 | ||||||||||||||||||||
| Exercised | (23,809) | $ | 8.10 | ||||||||||||||||||||
| Cancelled | (1,436,662) | $ | 30.43 | ||||||||||||||||||||
| Outstanding at December 31, 2024 | 7,656,010 | $ | 14.70 | 7.19 | $ | — | |||||||||||||||||
| Exercisable at December 31, 2024 | 3,964,202 | $ | 19.87 | 5.76 | $ | — | |||||||||||||||||
| Year Ended December 31, | |||||||||||||||||
| 2024 | 2023 | 2022 | |||||||||||||||
| Expected volatility | 75.6 | % | 75.2 | % | 64.2 | % | |||||||||||
| Expected option term (in years) | 6.20 | 6.19 | 6.25 | ||||||||||||||
| Risk free interest rate | 4.2 | % | 4.2 | % | 1.7 | % | |||||||||||
| Expected dividend yield | — | — | — | ||||||||||||||
About Stock Compensation Disclosures
Stock-based compensation disclosures detail the equity awards granted to employees and executives — including stock options, restricted stock units (RSUs), and performance shares — along with the valuation methods and assumptions used to expense them. This section reveals the true cost of talent retention and the alignment between management incentives and shareholder interests.
Key signals: total unrecognized compensation expense and its expected recognition period signal future earnings headwinds from already-granted awards. For stock options, examine Black-Scholes assumptions — expected volatility, risk-free rate, and expected term — as understating any of these reduces reported compensation expense. Compare stock compensation expense as a percentage of revenue against peers to assess dilution cost. Watch vesting schedules for acceleration clauses tied to change-of-control events. Performance-based awards with undemanding targets may indicate weak governance. Add back stock compensation to operating cash flow to calculate a more conservative free cash flow figure.